Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICSs), long-acting β 2-agonists (LABAs), and long-acting muscarinic …

Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …

Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …

Objective To compare the rate of moderate to severe exacerbations between triple therapy
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …

Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) …

Introduction Limited prospective evidence is available to guide selection of first-line
maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial …

Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …

This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …